---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-053115"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2023-10-12T23:59:59+00:00"
generated_at: "2026-06-10T00:54:37.366944+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences reports preclinical Gemini data showing biomarker activity; Phase 1 study planned

## Summary
- Gemini showed dose-dependent white blood cell mobilization and cytokine upregulation (IL-10, NGAL, IL-6) in healthy animal models.
- Data supports Gemini as a preventative therapy for infection and acute kidney injury; key biomarkers confirmed.
- Company plans to initiate a Phase 1 healthy volunteer study later this year, with full results to be published.
- Second dose of Gemini demonstrated attenuated IL-6 response indicating trained immunity; two-dose regimen being evaluated.

## SEC filing metadata
- accession: 0000950170-23-053115
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2023-10-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017023053115/0000950170-23-053115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017023053115/revb-20231012.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-053115
- JSON: https://secwatch.observer/filing/0000950170-23-053115.json
- Plain text: https://secwatch.observer/filing/0000950170-23-053115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.